<DOC>
	<DOCNO>NCT01837641</DOCNO>
	<brief_summary>The study evaluate safety LY3002813 look adverse event . The study also look effect body LY3002813 . Study participant healthy mild cognitive impairment ( MCI ) due Alzheimer 's disease ( AD ) mild moderate AD . There seven group study participant . Five group receive single dose LY3002813 placebo ( drug ) , follow 4 multiple dos LY3002813 placebo give injection vein . Approximately 12 week pas single dose first multiple dose . One group participant receive single dose LY3002813 give injection skin . One group participant receive single dose LY3002813 give injection vein .</brief_summary>
	<brief_title>A Study LY3002813 Participants With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Healthy Participants : Overtly healthy male , determine medical history physical examination , willing use reliable method birth control donate sperm study Between 18 40 year old . Body Mass Index ( BMI ) 18.0 30.0 kilogram per meter square ( kg/m^2 ) , inclusive Participants Mild Cognitive Impairment Due Alzheimer 's Disease ( AD ) AD : Present mild cognitive impairment ( MCI ) due AD mildtomoderate AD Men nonfertile woman , least 50 year age . Nonfertile define hysterectomy and/or bilateral oophorectomy , amenorrhea least 1 year Have caregiver/study informant provide separate write informed consent participate Have adequate vision hear neuropsychological test opinion investigator Positive florbetapir scan Healthy Participants : Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , immunological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Participants Mild Cognitive Impairment Due AD AD : Do reliable caregiver/study informant frequent contact participant , accompany participant office and/or available telephone designate time , monitor administration prescribe medication Are monitor radiation due occupational exposure ionize radiation , exposure ionize radiation within last 12 month investigational study History within past 5 year primary recurrent malignant disease exception resect cutaneous squamous cell carcinoma situ , basal cell carcinoma , cervical carcinoma situ , situ prostate cancer normal prostatespecific antigen post resection All Participants : History intracranial hemorrhage , cerebrovascular aneurysm arteriovenous malformation , carotid artery occlusion , stroke epilepsy Have contraindication magnetic resonance imaging ( MRI ) study , include claustrophobia , presence contraindicate metal ( ferromagnetic ) implant , cardiac pacemaker Have allergy humanize monoclonal antibody , include protein diphenhydramine , epinephrine , methylprednisolone Have gamma globulin therapy within last year Previously dose study investigate active immunization amyloid beta ( Aβ ) Previously dose study investigate passive immunization Aβ within last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>